A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

GSK Investigational Site, Edegem

GSK Investigational Site, Genk

GSK Investigational Site, Erpent

GSK Investigational Site, Ieper

GSK Investigational Site, Madrid

GSK Investigational Site, Madrid

GSK Investigational Site, Vic

GSK Investigational Site, Boadilla Del Monte (Madrid)

GSK Investigational Site, Marbella - Málaga

GSK Investigational Site, Benalmádena, Málaga

GSK Investigational Site, Nîmes

GSK Investigational Site, Tampere

GSK Investigational Site, Montpellier

GSK Investigational Site, Salamanca

GSK Investigational Site, Santander (Cantabria)

GSK Investigational Site, Valladolid

GSK Investigational Site, Angers

GSK Investigational Site, Seinäjoki

GSK Investigational Site, Clermont-Ferrand

GSK Investigational Site, Kokkola

GSK Investigational Site, Lyon

GSK Investigational Site, Pierre-Bénite

GSK Investigational Site, Paris

GSK Investigational Site, Limoges

GSK Investigational Site, Oulu

GSK Investigational Site, Espoo

GSK Investigational Site, Helsinki

GSK Investigational Site, Burgos

GSK Investigational Site, Centelles

GSK Investigational Site, La Roca Del Valles (Barcelona)

GSK Investigational Site, Soham

GSK Investigational Site, Bollington

GSK Investigational Site, Chippenham

GSK Investigational Site, Blackpool

GSK Investigational Site, Bristol

GSK Investigational Site, Chippenham

GSK Investigational Site, Peterborough